Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 14, 2024 1:20 PM ET Company Participants Ryan Crowe - SVP, IR David Snow - SVP, Global Head of Dupixent franchise Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great. Thank you, everybody, for joining us on the second day here of this track of the Oppenheimer Healthcare Conference of 2024. Got David Snow, the SVP and the Global Head of Dupixent franchise; and Ryan Crowe, ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 14, 2024 12:40 PM ET Company Participants Jacque Shea - President and CEO Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great, thank you operator for again, always making this so seamless and easy for us all. We have now Jacque Shea, the President and CEO of Inovio Company we've been covering for a while now. And we recently upgraded on the back of some really compelling data ...

Lockheed Martin Corporation (NYSE:LMT) TD Cowen 45th Annual Aerospace & Defense Conference February 14, 2024 10:00 AM ET Company Participants Jay Malave - Chief Financial Officer Conference Call Participants Cai von Rumohr - TD Cowen Cai von Rumohr Okay. So we're going to move on. We're delighted to have with us Lockheed Martin and their Jay Malave. And Jay, you're going to read a Reg FD statement to start. Jay Malave Statements made today that are not historical facts are considered forward-looking stateme ...

Amgen Inc. Conference Call Summary Company Overview - **Company**: Amgen Inc. (NASDAQ: AMGN) - **Event**: Oppenheimer 34th Annual Healthcare Life Sciences Conference - **Date**: February 14, 2024 Key Industry and Company Insights Growth Potential and Therapeutic Areas - Amgen is optimistic about growth across four therapeutic areas: General Medicine, Oncology, Inflammation, and Rare Disease [3][4] - The company emphasizes a balanced portfolio, reducing dependency on any single area for growth [4] Obesity Program - MariTide - MariTide is highlighted as a lead program with a differentiated profile in obesity treatment [3] - Phase I data shows promising results, with a 14.5% weight loss after three monthly doses in a high-dose cohort [13] - Durability of weight loss is notable, with approximately 11% maintained after 150 days post-treatment [14] - A Phase II study with 592 patients is underway, focusing on various dosing regimens, with interim analysis expected mid-2024 [14][15] Product Performance and Sales Growth - In 2023, Amgen reported a 15% year-over-year volume growth and 9% product sales growth, driven by 18 products achieving record sales [5] - Specific products like Repatha and EVENITY showed significant growth, with Repatha at 37% and EVENITY at 44% year-over-year [6] Oncology Developments - BLINCYTO is expected to see growth due to positive Phase III data and updated NCCN guidelines [7] - Tarlatamab, a first-in-class medicine for small cell lung cancer, is set for a June PDUFA date, indicating strong potential for market entry [7][49] Inflammation Portfolio - Otezla continues to show growth potential, with a 6% increase in new patient starts in Q4 2023 [8][40] - TEZSPIRE recorded sales of $177 million in Q4 2023, with a total of $567 million for the year [8] Rare Disease Pipeline - Amgen is expanding its Rare Disease growth pillar, with more details to be shared in an upcoming investor event [9][51] Market Positioning and Commercial Strategy - The company plans to position MariTide with a focus on monthly or less frequent dosing, enhancing patient experience [31][36] - The potential market opportunity for MariTide is significant, targeting hundreds of millions of individuals with obesity [37] Competitive Landscape - Amgen is leveraging human genetic insights to inform drug design, particularly for obesity treatments [17][18] - The company is confident in MariTide's differentiated approach compared to existing therapies, focusing on efficacy, tolerability, and patient adherence [36][37] Future Outlook - Amgen's pipeline includes multiple first-in-class or best-in-class medicines across all therapeutic areas, with key data readouts anticipated in 2024 [9][10] - The company is committed to enhancing patient experience through innovative delivery methods and dosing strategies [31][32] Additional Important Points - The company is actively engaging with the medical community, leading to rapid enrollment in ongoing studies [22] - Amgen's manufacturing capabilities are positioned to support the commercial formulation of MariTide [31][32] - The upcoming rare disease event aims to provide insights into Amgen's newest therapeutic area [51]

Uber Technologies, Inc. (NYSE:UBER) Virtual Investor Update Call February 14, 2024 8:00 AM ET Company Participants Dara Khosrowshahi - Chief Executive Officer Andrew Macdonald - Senior Vice President, Mobility and Business Operations Pierre-Dimitri Gore-Coty - Senior Vice President, Delivery Jill Hazelbaker - Senior Vice President, Marketing and Public Affairs Prashanth Mahendra-Rajah - Chief Financial Officer Alax Wang - Head of Investor Relations Dara Khosrowshahi Good morning, and on behalf of all of tea ...

Company and Industry Overview * **Company**: General Dynamics Corporation (NYSE: GD) * **Industry**: Aerospace & Defense * **Event**: TD Cowen 45th Annual Aerospace & Defense Conference * **Date**: February 13, 2024 * **Participants**: Phebe Novakovic (CEO, General Dynamics) and Cai von Rumohr (TD Cowen) Key Takeaways 2023 Performance and Outlook * **Revenue Growth**: General Dynamics achieved strong revenue growth in 2023, driven by defense revenue and increased deliveries. * **Margin Improvement**: The company expects margin improvement in 2024, driven by volume mix, cost efficiency, and reduced R&D expenses. * **Earnings Growth**: General Dynamics anticipates additional earnings growth as a result of revenue growth and margin improvement. Aerospace Segment * **Gulfstream**: Gulfstream deliveries are expected to increase by 44% in 2024, driven by strong demand and the ramp-up of the G700 program. * **Supply Chain**: The aerospace supply chain is improving, but there are still challenges, particularly in out-of-station work. * **Labor Market**: Gulfstream does not face labor issues, while the Marine Group has seen improved hiring and training programs. Marine Segment * **Marine Group**: The Marine Group is focused on increasing throughput and productivity to offset supply chain challenges and cost impacts. * **Supply Chain**: The marine supply chain is improving, but there are still elements that need further improvement. * **Labor Market**: The Marine Group has seen increased hiring and training programs, leading to improved productivity. Combat Systems Segment * **Combat Systems**: The Combat Systems segment is well-positioned for growth through 2026, driven by strong demand for munitions and land systems. * **Munitions**: The company has tripled 155mm production in two years and is focused on replenishing stockpiles. * **Land Systems**: Demand for land systems is increasing in Europe, Asia, and the United States. Technology Segment * **Technology**: The Technology segment is expected to grow at a low single-digit rate, driven by new orders and margin improvement. * **Mission Systems**: Mission Systems is expected to achieve a solid book-to-bill ratio and see growth in space orders. * **Technology**: The Technology segment is focused on increasing margins as it ramps up on newer programs. Financials * **Cash Flow**: General Dynamics expects strong cash flow conversion, driven by improved operating performance and reduced capital expenditures. * **Capital Deployment**: The company plans to focus on share repurchases, with a bias towards opportunistic purchases. Risks * **Supply Chain**: The stability of the supply chain remains a key risk. * **Geopolitical Events**: Unexpected geopolitical events could impact the company's business. * **Macroeconomic Stress**: Macroeconomic stress could impact the company's business and demand for defense products. Conclusion General Dynamics is well-positioned for growth in 2024 and beyond, driven by strong demand for defense products, improved operating performance, and prudent capital deployment. The company is focused on margin improvement and driving value for its customers, employees, and shareholders.

Editas Medicine, Inc. (NASDAQ:EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 8:40 AM ET Company Participants Dr. Baisong Mei - Senior Vice President and Chief Medical Officer Conference Call Participants Jay Olson - Oppenheimer Jay Olson Hello everyone and welcome to Oppenheimer’s 34th Annual Healthcare Conference. I am Jay Olson, one of the biotech analysts at Oppenheimer and I want to thank you for joining us. It's my pleasure to welcome Editas to our conference, and i ...

Boeing Co (NYSE:BA) TD Cowen 45th Annual Aerospace and Defense Conference Call February 13, 2024 10:45 AM ET Company Participants Brian West - EVP, Finance & CFO Conference Call Participants Cai von Rumohr - TD Cowen Cai von Rumohr Time. Thank you all for coming. We're delighted to have with us The Boeing Company. And from Boeing, we've got Brian West, the CFO. And Brian, you may want to make some forward-looking comments first or comments about forward-looking comments? Brian West It's in front of the scre ...

Summary of RTX Corporation Conference Call Company Overview - **Company**: RTX Corporation (NYSE: RTX) - **Date**: February 13, 2024 - **Participants**: Neil Mitchill (CFO), Cai von Rumohr (TD Cowen) Key Points Financial Performance - **2023 Sales**: Over $74 billion, up 11% organically, driven by strong performance across all three segments: Pratt & Whitney, Collins Aerospace, and Raytheon [2][3] - **2024 Sales Outlook**: Projected sales of $78 billion to $79 billion, representing 7% to 8% organic growth [5] - **Free Cash Flow**: Expected to grow from $5.5 billion in 2023 to $5.7 billion in 2024, and further to $7.5 billion in 2025 [3] Backlog and Execution - **Record Backlog**: Ended 2023 with a backlog of $196 billion, with 60% expected to unfold over the next two years, particularly in defense [3][6] - **Key Drivers**: Focus on executing production contracts and addressing supply chain challenges to meet customer commitments [6] Supply Chain and Labor - **Supply Chain Status**: Described as stabilizing to improving, with ongoing efforts to enhance delivery from over 450 key suppliers [8][10] - **Inflation Impact**: Experienced $2.3 billion in inflation in 2023, expected to reduce to $1.7 billion in 2024 due to pricing adjustments and cost-reduction activities [11] - **Labor Retention**: Significant improvement in retention rates, though challenges remain in hiring qualified personnel for specialized roles [13][14] Segment Insights - **Commercial Aftermarket**: Anticipated growth of 10% in 2024, following a 23% increase in 2023, with aftermarket expected to contribute significantly to profit growth [20][21] - **Narrow-body vs. Wide-body**: Narrow-body OE sales are recovering well, while wide-body sales remain below 2019 levels, indicating potential for future growth [17][18] Raytheon and Defense Outlook - **Defense Business Challenges**: Facing pressures from supply chain constraints and fixed-price development programs, with expectations to resolve most issues by the end of 2025 [44][46] - **Strong Demand**: Anticipated book-to-bill ratio over 1.0, driven by international orders and demand for air defense systems [53][54] - **Margin Improvement**: Expected to improve as international orders increase and fixed-price contract issues are resolved [55][56] Capital Allocation and M&A Strategy - **Capital Commitment**: $36 billion to $37 billion through 2025, primarily focused on dividends and some ancillary buybacks [68] - **M&A Strategy**: Currently not pursuing large M&A but open to bolt-on acquisitions that enhance existing technologies [69] Risks and Opportunities - **Cash Flow Risks**: Dependent on volume and demand for aftermarket services; potential challenges in working capital if volume does not meet expectations [65][66] - **Powder Metal Issue**: Estimated $3 billion cash impact over the next few years, with ongoing efforts to manage customer support agreements [66] Additional Insights - **Inventory Management**: Focus on optimizing inventory levels to align with sales forecasts and improve cash flow [63] - **Aftermarket Growth**: Significant potential for aftermarket growth as more aircraft come off warranty, contributing to higher profit margins [58][59] This summary encapsulates the key insights and financial outlook for RTX Corporation as discussed in the conference call, highlighting both opportunities and challenges within the aerospace and defense sectors.

Vinci SA (OTCPK:VCISF) 2023 Annual Results Earnings Conference Call February 8, 2024 4:30 AM ET Company Participants Xavier Huillard – Chairman and Chief Executive Officer Christian Labeyrie – Executive Vice-President and Chief Financial Officer Pierre Anjolras – Chairman-VINCI Construction Nicolas Notebaert – Chief Executive Officer-VINCI Concessions Arnaud Grison – Chairman and Chief Executive Officer-VINCI Energies Conference Call Participants Jean-Christophe – CM-CIC Luis Prieto – Kepler Gregor Kuglitsc ...